A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination with Cemiplimab-rwlc (Libtayo ) in Subjects with Recurrent or Progressive Glioblastoma

Brief description of study

The purpose of this research study is to evaluate the safety and tolerability of intratumorally injected Ad-RTS-hIL-12 combined with oral veledimex, a viral gene therapy, in combination with cemiplimab-rwlc, a PD-1 inhibitor, in patients with recurrent glioblastoma.

Clinical Study Identifier: s19-00086
ClinicalTrials.gov Identifier: NCT04006119
Principal Investigator: Sylvia C. Kurz
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.